Golimumab

證據等級: L5

預測適應症: 5 個

Golimumab: From Approved Inflammatory Arthritis Indications to Rheumatoid Vasculitis

One-Sentence Summary

Golimumab is a fully human anti-TNF-α monoclonal antibody with established indications in inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis per published literature). The TxGNN model's top-ranked prediction suggests potential efficacy for Rheumatoid Vasculitis, but the supporting evidence is mixed — 3 loosely related clinical trials and 6 publications, including case reports that describe anti-TNF therapy both treating and paradoxically inducing vasculitis. This evidence pack (TW-DB06674-multi) contains four additional candidate indications; two of them (ranked #3 and #5) are substantially better supported and are summarized at the end of this report.

Quick Overview

Item	Content
Original Indication	Not available from formal license data (golimumab is not currently marketed in this jurisdiction); literature confirms approved use for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular JIA elsewhere
Predicted New Indication	Rheumatoid Vasculitis
TxGNN Prediction Score	99.73% (rank 3700 in model output)
Evidence Level	L4
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Structured DrugBank mechanism-of-action data is not available in this evidence pack (original_moa: [Data Gap]). Based on the literature retrieved, golimumab is a fully human anti-TNF-α IgG1κ monoclonal antibody administered subcutaneously (or intravenously), approved for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis (PMID 28530020, 20065639).

Rheumatoid vasculitis is a severe extra-articular manifestation of long-standing, seropositive rheumatoid arthritis, driven by immune complex deposition and TNF-mediated vascular inflammation. Mechanistically, suppressing TNF-α could plausibly reduce this vasculitic process, and one case report notes that the incidence of rheumatoid vasculitis has declined since biologic DMARDs (including anti-TNF agents) entered practice (PMID 29075910).

However, the evidence is not one-directional. A case report of two patients who developed Takayasu's arteritis while on anti-TNF therapy (PMID 22999907) illustrates a recognized "paradoxical vasculitis" phenomenon associated with this drug class — anti-TNF agents can, in some patients, trigger or unmask vasculitic disease rather than treat it. This directionally inconsistent signal is the main reason the evidence level is capped at L4 (mechanism/case-report level) despite the very high TxGNN score, and why the current recommendation is to Hold pending safety clarification.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07138898	Phase 2	Not Yet Recruiting	80	Evaluates perioperative immunosuppressant (incl. anti-TNF) management in rheumatology patients undergoing shoulder arthroplasty; population overlap only, not vasculitis-specific
NCT05696106	N/A	Unknown	750,000	Large real-world study on risk of new immune-mediated inflammatory disease (IMID) onset after biologic treatment for a single IMID; may capture vasculitis as an outcome but not as a primary endpoint
NCT01579006	N/A	Completed	184	Non-interventional study of a biologic (tocilizumab, not golimumab) in RA patients with inadequate DMARD response; included for RA population overlap, not golimumab- or vasculitis-specific

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31491879	2019	Network Meta-Analysis	Int J Mol Sci	Compares golimumab and other TNF inhibitors across 36 RCTs for radiographic joint destruction in RA; strong comparative efficacy data but no vasculitis endpoint
23557513	2013	Review	BMC Medicine	Overview of biologic therapies (including anti-TNF agents) for autoimmune/rheumatologic disease, general efficacy/safety context
27591827	2017	Cohort	Semin Arthritis Rheum	Frequency and causes of end-stage renal disease in RA patients; relevant to extra-articular RA burden but not vasculitis-specific
29075910	2018	Case Report	Rheumatol Int	Severe sepsis (pyoderma gangrenosum/pyogenic arthritis) in an RA patient on golimumab; notes rheumatoid vasculitis incidence has declined since anti-TNF agents were introduced
22999907	2013	Case Report	Joint Bone Spine	Two cases of Takayasu's arteritis occurring under anti-TNF therapy — paradoxical vasculitis-induction signal that contradicts the therapeutic hypothesis
23252659	2013	Case Report	Ocul Immunol Inflamm	Behçet disease-associated uveitis (a vasculitis-related condition) successfully treated with golimumab — a positive counter-signal

Germany Market Information

Golimumab is currently not marketed in this jurisdiction — no authorization records are on file (total_licenses: 0).

Safety Considerations

Structured safety data (key warnings, contraindications, DDI) is not currently available for this drug in this evidence pack.

Evidence-derived safety signal (not from structured safety data): Literature includes a case report of anti-TNF-associated paradoxical vasculitis (Takayasu's arteritis onset during anti-TNF therapy, PMID 22999907). This directly relevant safety signal should be resolved before pursuing rheumatoid vasculitis as an indication.

Please refer to the package insert for full safety information once available (see Data Gap DG001 below).

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale for anti-TNF therapy in rheumatoid vasculitis is plausible but not consistently supported — literature evidence includes both a protective signal (declining vasculitis incidence since anti-TNF introduction) and a contradictory signal (anti-TNF-induced vasculitis case reports). No clinical trial directly and adequately evaluates golimumab for this indication. Evidence level is L4 (case report/mechanism only).

To proceed, the following is needed:

TFDA/BfArM package insert warnings and contraindications (Data Gap DG001, Blocking — required before any S1 safety screening)
Structured mechanism-of-action data from DrugBank (Data Gap DG002, High)
A dedicated literature review to reconcile the therapeutic-vs-paradoxical vasculitis signal for anti-TNF agents
A clinical trial or registry study with rheumatoid vasculitis as a primary or explicit secondary endpoint

Other Candidate Indications in This Evidence Pack

This evidence pack evaluated 5 candidate indications for golimumab. The other four, ranked by TxGNN, are summarized below — two are substantially better supported than the top-ranked prediction above and warrant separate, dedicated evaluation.

Rank	Indication	TxGNN Score	Evidence Level	Decision	Note
3	Inflammatory spondylopathy	99.66%	L1	Proceed with Guardrails	Strongest candidate — golimumab is already an approved anti-TNF therapy for ankylosing spondylitis, nr-axSpA, and psoriatic arthritis, supported by numerous completed Phase 3/4 RCTs (e.g., NCT00265083, NCT02186873, NCT03270501) and systematic reviews (PMID 36270657, 38503473). This is largely an existing-indication extension rather than novel repurposing.
5	Polyarticular juvenile rheumatoid arthritis	99.59%	L1	Proceed with Guardrails	Also strongly supported — golimumab (SC and IV) is already FDA-approved for polyarticular JIA, backed by completed Phase 3 RCTs (NCT01230827, NCT02277444) and long-term extension safety data (PMID 33493312, 28507219, 39089836). Continued monitoring needed for pediatric long-term immunosuppression risk (infection, malignancy).
2	Hypermobility of coccyx	99.67%	L5	Hold	No clinical trials or literature; no plausible biological link to TNF-α inhibition. Likely knowledge-graph noise.
4	Kummell disease	99.61%	L5	Hold	No clinical trials or literature; vertebral ischemic collapse has no mechanistic connection to golimumab. Likely knowledge-graph noise.

Recommendation: Prioritize separate, dedicated evaluation reports for inflammatory spondylopathy and polyarticular JIA (rank 3 and 5) — these represent the strongest, most actionable findings in this evidence pack and are far more decision-ready than the top-ranked rheumatoid vasculitis prediction. Ranks 2 and 4 can be deprioritized as low-confidence model output.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.